MCT4 alleviates lipid accumulation, inflammation and PANoptosis in non-alcoholic fatty liver disease by inhibiting JAK-STAT signaling transduction | Synapse
March 3, 2026Open Access
MCT4 alleviates lipid accumulation, inflammation and PANoptosis in non-alcoholic fatty liver disease by inhibiting JAK-STAT signaling transduction
Key Points
MCT4 significantly alleviates lipid accumulation and inflammation in NAFLD by inhibiting the JAK-STAT pathway, which is crucial for these processes.
Lipid accumulation decreased notably alongside inflammatory responses within 6 weeks in model studies with MCT4 treatment.
Assessment using signaling transduction analysis reveals MCT4's role in dampening the JAK-STAT pathway's effects on liver health.
This finding highlights MCT4 as a potential target for developing effective NAFLD therapies, though further research is needed.
Abstract
MCT4 provides new reference for the treatment of NAFLD by inhibiting the JAK-STAT pathway, slowing down lipid accumulation and inflammatory response in NAFLD.